Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Circulatory

  • News

    Reversal agents curb DOAC-related bleeding but deaths still high

    June 17, 2021

    The meta-analysis of more than 4,000 patients also showed thrombotic events were more frequent with andexanet than with 4PCC or idarucizumab.

  • News

    Are left atrial thrombi that defy preprocedure anticoagulation predictable?

    June 11, 2021

    Features that predispose to such persistent LA thrombi, which are not very rare, could potentially guide more targeted TEE screening before rhythm-control procedures.

  • News

    First risk score to predict bleeding risk after TAVR

    June 11, 2021

    PREDICT-TAVR was developed and validated in two national registries in Europe and outperformed existing risk scores developed outside TAVR.

  • 1
    News

    Single subcutaneous shot offers fast, potent platelet inhibition in STEMI

    June 1, 2021

    The effect was seen within 15 minutes of receiving RUC-4, an investigational glycoprotein IIb/IIIa inhibitor, with no thrombocytopenia, in a phase 2a study.

  • 1
    News

    New AHA/ASA guideline on secondary stroke prevention

    May 27, 2021

    Identifying the cause of a first stroke or transient ischemic attack is key to developing strategies to prevent repeat events, the AHA/ASA says in an updated clinical practice guideline.

  • 1
    News

    Update in Hospital Medicine relays important findings

    May 13, 2021

    Two panelists highlighted the year of research in areas most relevant and important to hospital medicine.

  • 1
    News

    Trends in the management of pulmonary embolism

    May 7, 2021

    After completion of primary treatment for patients with unprovoked DVT and/or PE, guidelines suggest indefinite antithrombotic therapy over stopping anticoagulation.

  • News

    Ruling out PE in patients with low C-PTP and D dimer of less than 1,000 ng/mL

    April 30, 2021

    Can we rule out pulmonary embolism (PE) in patients with a low clinical pretest probability (C-PTP) and a D dimer of less than 1,000 ng/mL?

  • 1
    News

    FDA, CDC urge pause of J&J COVID vaccine

    April 13, 2021

    Treatment for traditional blood clots, such as the drug heparin, should not be used for these clots.

  • News

    Novel antiplatelet drug: Hope for efficacy without bleeding?

    April 12, 2021

    A new antiplatelet drug with a completely novel mechanism of action could hold the promise of delivering the holy grail – reducing cardiac events without increasing bleeding.

Previous1 2 3 4 5 6 … 25Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences